Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection

scientific article published on April 2009

Emerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.2147/TCRM.S3137
P932PMC publication ID2697544
P698PubMed publication ID19536321

P50authorChristine KatlamaQ47006550
Robert L. MurphyQ39793026
P2860cites workTrial and failureQ59034419
AIDS research. Trials of NIH's AIDS vaccine get a yellow lightQ64376855
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsQ79390358
Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patientsQ80176025
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzymeQ45402590
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trialQ45405108
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infectionQ46466415
RaltegravirQ46519904
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phaseQ46843159
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlationQ46852183
Vaginal microbicides: moving ahead after an unexpected setback.Q50859418
Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.Q51740971
The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?Q24652185
Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)Q24656978
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled studyQ28242324
A historical sketch of the discovery and development of HIV-1 integrase inhibitorsQ28274166
Raltegravir with optimized background therapy for resistant HIV-1 infectionQ28288290
Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cellsQ28369295
CD4+ count-guided interruption of antiretroviral treatmentQ29619489
In-Silico docking of HIV-1 integrase inhibitors reveals a novel drug type acting on an enzyme/DNA reaction intermediateQ30479242
Integrase inhibitors to treat HIV/AIDS.Q34397376
Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infectionQ37039007
Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infectionQ37043546
Inhibitors of human immunodeficiency virus type I integrationQ37446895
Repair of gaps in retroviral DNA integration intermediatesQ39597824
P275copyright licenseCreative Commons Attribution-NonCommercial 3.0 UnportedQ18810331
P6216copyright statuscopyrightedQ50423863
P433issue2
P304page(s)331-340
P577publication date2009-04-01
P1433published inTherapeutics and Clinical Risk ManagementQ15766913
P1476titleEmerging role of integrase inhibitors in the management of treatment-experienced patients with HIV infection
P478volume5

Reverse relations

cites work (P2860)
Q37775505Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors.
Q37989555Dolutegravir for the treatment of HIV.
Q37982825Elvitegravir: a once-daily inhibitor of HIV-1 integrase
Q33991491Microwave assisted organic synthesis (MAOS) of small molecules as potential HIV-1 integrase inhibitors.
Q42283539Synthesis and biological evaluation of novel antiviral agents as protein-protein interaction inhibitors
Q38009758Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)?
Q40706247Treatment durability and virological response in treatment-experienced HIV-positive patients on an integrase inhibitor-based regimen: an Australian cohort study.

Search more.